Friday, June 20th, 2025
Stock Profile: ARQT

Arcutis Biotherapeutics, Inc. (ARQT)

Market: NASD | Currency: USD

Address: 3027 Townsgate Road

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly Show more




📈 Arcutis Biotherapeutics, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Arcutis Biotherapeutics, Inc.


DateReported EPS
2025-11-04 (estimated upcoming)-
2025-11-03 (estimated upcoming)-
2025-08-12 (estimated upcoming)-
2025-08-11 (estimated upcoming)-
2025-05-12-
2025-05-11-
2025-02-25-0.09
2025-01-12-
2024-11-06-0.33
2024-08-14-0.42
2024-08-13-0.42
2024-05-14-0.32
2024-05-13-0.32
2024-02-27-0.72
2024-02-26-0.72
2023-11-03-0.73
2023-11-02-0.73
2023-08-08-1.16
2023-08-07-1.16
2023-05-09-1.31
2023-05-08-1.31
2023-02-28-1.18
2023-02-27-1.18
2022-11-08-1.89
2022-11-07-1.89
2022-08-04-1.31
2022-08-03-1.31
2022-05-05-1.27
2022-05-04-1.27
2022-02-22-1.42
2022-02-21-1.42
2021-11-04-1.14
2021-11-03-1.14
2021-08-05-0.84
2021-08-04-0.84
2021-05-04-0.76
2021-05-03-0.76
2021-02-16-0.79
2021-02-15-0.79
2020-11-05-1.01
2020-11-04-1.01
2020-08-11-0.94
2020-08-10-0.94
2020-05-12-1.15
2020-05-11-1.15
2020-03-18-6.18
2020-01-30-




📰 Related News & Research


No related articles found for "arcutis biotherapeutics".